凛冬将至?渤健 、FibroGen、Infinity Pharmaceuticals 等密集裁员、砍管线、停临床

医药经济报
28 Jul 2023

七月开始,海外多家跨国药企正在勒紧裤腰带,宣布裁员和重组计划。渤健7月25日,渤健(Biogen)发布2023H1财报,上半年营收49.19亿美元,同比下滑4%,净利润为9.81亿美元,同比下滑23.2%,研发投入11.55亿美元,同比增长6.9%。多发性硬化症产品销售额继续下滑,上半年总收入23.35亿美元。同时,渤健还宣布了一项新的“Fit for Growth”计划,预计将节省约10亿美元的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10